Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor
The Cleveland Clinic · NCT06293638
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 30–80 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 55
- US sites recruiting
- 1
- Study start
- March 25, 2024
- Record last updated
- May 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will either 1) have electroencephalography (EEG) scalp electrodes placed, or 2) remain seated with their head inside of a magnetoencephalography (MEG) recording system, as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of the following: 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.
Being studied: Alcohol; Alprazolam; Cold Therapy; Peripheral Nerve Stimulation
Conditions: Essential Tremor
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Between 30 and 80 years of age;
- Ability to provide informed consent;
- Clinical diagnosis of ET by a movement disorders neurologist with a disease duration of at least 3 years and being treated with a DBS; OR
- Clinical diagnosis of ET by a movement disorders neurologist with a disease duration of at least 3 years and not being treated with a DBS; OR
- No known neurological disease or disorder.
Exclusion Criteria
- The individual has a condition that, in the opinion of the investigator, would significantly increase the risk for interference with study compliance, safety, or outcome;
- Presence of active psychiatric symptoms meeting Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV) criteria for Axis-I disorder on formal psychiatric evaluation other than depression or anxiety;
- History of cognitive impairment meeting Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV) criteria for dementia on formal neuropsychological evaluation, as documented in chart;
- Lack of English-language fluency which would interfere with the ability to understand the study consenting process and potential study risks;
- Hearing or visual impairment precluding testing;
- Motor impairment impacting test responses (i.e., orthopedic injury or disease);
- Anyone currently taking medications with Antabuse-like effects (e.g. Flagyl, Bactrim, Tindamax) will be excluded from any alcohol administration.
Recruiting US locations
Cleveland Clinic
Cleveland, OH 44195
Site contact: Jeff Negrey, MA · 216-636-5504 · negreyj2@ccf.org
Study contacts (from the official record)
- Jeffrey Negrey, MA · 2163166896 · negreyj2@ccf.org
- Madeline Porter · 2167691866 · porterm11@ccf.org
Similar studies in Ohio
All neurology studies in Ohio →- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Cincinnati, OH + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Columbus, OH + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd.
- Location
- Beachwood, OH + 16 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Cincinnati, OH + 35 other US sites
- Eligibility basics
- Ages 18–65